Compositions and Methods of Making Sustained Release Liquid Formulations

Abstract

The present invention includes compositions and methods for the controlled release of active agents in a shelf-stable liquid formulation by blending one or more controlled release microbeads comprising one or more active agents, preparing a dense, thixotropic solution having a density that is at, or about, the density of the one or more microbeads comprising a thixotropic agent, water and one or more preservatives under conditions that reduce bubble formation and mixing the microbeads and the thixotropic solutions in a mixer that lacks scraping paddles.

1 - 34 . (canceled) 
     
     
         35 . A liquid, controlled-release formulation comprising controlled release microbeads comprising one or more active agents in coated drug-resin complexes, a dense, thixotropic solution having a density that is at or about the density of the one or more microbeads, said dense, thixotropic solution comprising a thixotropic agent, water and one or more preservatives,
 wherein said formulation is shelf-stable and has a uniform appearance with no visible lumps, and   further wherein said formulation is made by the method of   obtaining one or more controlled release microbeads comprising one or more active agents in coated drug-resin complexes;   preparing a dense, thixotropic solution having a density that is at or about the density of the one or more microbeads, wherein the dense, thixotropic solution comprises a thixotropic agent, water and one or more preservatives, under conditions that reduce bubble formation; and   mixing the microbeads and the thixotropic solutions under conditions that minimize the introduction of bubbles in the liquid.   
     
     
         36 . The liquid formulation of  claim 35 , wherein the one or more active agents comprises pseudoephedrine, salts thereof or mixtures of salts thereof. 
     
     
         37 . The liquid formulation of  claim 35 , wherein the one or more active agents comprises an antihistamine. 
     
     
         38 . The liquid formulation of  claim 35 , wherein the one or more active agents comprises chlorpheniramine, salts thereof or mixtures of salts thereof. 
     
     
         39 . The liquid formulation of  claim 35 , wherein the one or more active agents comprises dextromethorphan, salts thereof or mixtures of salts thereof. 
     
     
         40 . (canceled) 
     
     
         41 . The liquid formulation of  claim 35 , wherein the one or more active agents comprises an analgesic. 
     
     
         42 . The liquid formulation of  claim 35 , wherein the one or more active agents comprises an antitussive. 
     
     
         43 . (canceled) 
     
     
         44 . A liquid, controlled-release formulation comprising controlled release beads comprising one or more active agents in coated drug-resin complexes with a dense, thixotropic solution having a density that is at or about the density of the one or more beads, wherein the dense, thixotropic solution comprises a thixotropic agent, water and one or more preservatives,
 wherein said formulation is shelf-stable and has a uniform appearance with no visible lumps, and   further wherein said formulation is made by the method of   blending one or more controlled release beads comprising one or more active agents in coated drug-resin complexes with a dense, thixotropic solution with a density that is at or about the density of the one or more beads, wherein the dense, thixotropic solution comprises a thixotropic agent, water and one or more preservatives, under conditions that minimize air bubbles which cling to said beads.   
     
     
         45 . The liquid formulation of  claim 44 , wherein said method comprises the step of blending a mixture comprising one or more controlled-release beads comprising one or more active agents, a thickening agent and a surfactant by mixing with a low cavitation propeller and recirculating the mixture under the surface of the mixture so as to minimize bubble formation. 
     
     
         46 - 60 . (canceled) 
     
     
         61 . The liquid formulation of  claim 35 , wherein the one or more microbeads comprise one or more of the following: an enteric coat, a resin coat, a lacquer coat, a pH-sensitive coating, a biodegradable polymer matrix, a water soluble matrix, an ionic matrix, combinations and mixtures thereof. 
     
     
         62 . The liquid formulation of  claim 35 , wherein the one or more microbeads comprise one or more polymers selected from the group consisting of cellulose, ethylcellulose, methylcellulose, propylcellulose, methoxypropylcellulose, cellulose nitrate, poly(vinyl alcohol), poly(vinyl chloride), polystyrene, polyethylene, polypropylene, poly(ethylene-co-vinyl acetate), poly(hydroxybutyric acid), poly(hydroxyvalerianic acid-co-hydroxybutyric acid), poly(lactic acid), poly(glycolic acid), poly(lactic acid-co-glycolic acid), poly(ε-caprolactones), poly(ε-caprolactone-co-DL-lactic acid), poly(maleic anhydride), polyamides, gelatin, chitosan, collagen, poly(hydroxyalkyl)-L-glutamines, poly(γ-ethyl-L-glutaminate-co-glutamic acid), poly(L-leucine-co-L-aspartic acid), poly(proline-co-glutamic acid), poly(alkyl 2-cyanoacrylates), polyurethanes, poly(methyl methacrylate), poly(methyl methacrylate-co-methacrylic acid) and poly(methacrylate-co-hydroxypropyl methacrylate), polystirex, salts, combinations and mixtures thereof. 
     
     
         63 . The liquid formulation of  claim 35 , wherein the conditions that reduce bubble formation comprise the step of using a diaphragm pump to combine the water and the thixotropic agent and one or more preservatives, colorants and flavorants. 
     
     
         64 . The liquid formulation of  claim 35 , wherein the conditions that reduce bubble formation and/or minimize the introduction of bubbles comprise the step of placing the recirculating tube below the surface of the liquid. 
     
     
         65 . The liquid formulation of  claim 35 , wherein the conditions that reduce bubble formation and/or minimize the introduction of bubbles comprise the step of adding liquids along the side of a vessel holding the liquid. 
     
     
         66 . The liquid formulation of  claim 35 , wherein the conditions that minimize the introduction of bubbles comprise the step of sprinkling the beads onto the surface of the liquid. 
     
     
         67 . The liquid formulation of  claim 35 , wherein the conditions that minimize the introduction of bubbles comprise the step of mixing the solution in the absence of one or more paddles that scrape the vessel. 
     
     
         68 . The liquid formulation of  claim 35 , wherein the conditions that reduce bubble formation comprise the step of using a diaphragm pump to combine one or more of the water, the thixotropic agent, the one or more preservatives, colorants and flavorants. 
     
     
         69 . The liquid formulation of  claim 35 , wherein the conditions that reduce bubble formation and/or minimize the introduction of bubbles comprise the steps of:
 placing a recirculating tube below the surface of the liquid;   adding liquids along the side of a vessel holding the liquid; and   using a mixer that lacks scraping paddles.   
     
     
         70 . The liquid formulation of  claim 35 , wherein the conditions that reduce bubble formation and/or minimize the introduction of bubbles comprise the step of mixing the solution with a propeller mixer. 
     
     
         71 . The liquid formulation of  claim 35 , wherein the conditions that reduce bubble formation and/or minimize the introduction of bubbles comprise the step of mixing the solution with a propeller mixer at a speed that reduces cavitation. 
     
     
         72 . The liquid formulation of  claim 35 , wherein the conditions that reduce bubble formation and/or minimize the introduction of bubbles comprise the step of mixing the solution with a propeller that minimizes cavitation. 
     
     
         73 . The liquid formulation of  claim 35 , wherein a portion of the one or more beads comprises an immediate release profile and another portion comprise a delayed release profile. 
     
     
         74 . The liquid formulation of  claim 35 , wherein the formulation further comprises one or more flavorants, one or more surfactants, one or more dissolved active agents, one or more buffers, one or more excipients, or mixtures and combinations thereof. 
     
     
         75 . The liquid formulation of  claim 35 , wherein the one or more active agents are pharmaceutical agents. 
     
     
         76 . The liquid formulation of  claim 35 , wherein the one or more active agents comprise vitamins, minerals, nutritional supplements, herbal extracts, gums, gels, oils, salts, or mixtures and combinations thereof. 
     
     
         77 . The liquid formulation of  claim 35 , wherein the one or more active agents are pharmaceutical agents selected from the group consisting of protein, peptide, carbohydrate, polysaccharide, glycoprotein, lipid, hormone, growth factor, cytokine, interferon, receptor, antigen, allergen, antibody, antiviral, antifungal, antihelminthic, substrate, metabolite, cofactor, inhibitor, drug, pharmaceutical, nutrient, toxin, poison, explosive, pesticide, chemical warfare agent, biowarfare agent, biohazardous agent, infectious agent, prion, radioisotope, vitamin, heterocyclic aromatic compound, carcinogen, mutagen, narcotic, amphetamine, barbiturate, hallucinogen, combinations and mixtures thereof. 
     
     
         78 . The liquid formulation of  claim 35 , wherein the one or more active agents comprise a pharmaceutical agent, an enzyme, a cytokine, a growth promoting agent, an antibody, an antigen, a hormone, a vaccine, a cell, a live-attenuated pathogen, a heat-killed pathogen, a virus, a bacteria, a fungi, a peptide, a carbohydrate, a nucleic acid, a lipid, or mixtures and combinations thereof. 
     
     
         79 . The liquid formulation of  claim 35 , wherein the one or more active agents may be steroids, respiratory agents, sympathomimetics, local anesthetics, antimicrobial agents, antiviral agents, antifungal agents, antihelminthic agents, insecticides, antihypertensive agents, antihypertensive diuretics, cardiotonics, coronary vasodilators, vasoconstrictors, β-blockers, antiarrhythmic agents, calcium antagonists, anti-convulsants, agents for dizziness, tranquilizers, antipsychotics, muscle relaxants, drugs for Parkinson's disease, respiratory agents, hormones, non-steroidal hormones, antihormones, vitamins, antitumor agents, miotics, herb medicines, antimuscarinic, interfereons, immunokines, cytokines, muscarinic cholinergic blocking agents, mydriatics, psychic energizers, humoral agents, antispasmodics, antidepressant drugs, anti-diabetics, anorectic drugs, anti-allergenics, decongestants, expectorants, antipyretics, antimigrane, anti-malarials, anti-ulcerative, peptides, anti-estrogen, anti-hormone agents, antiulcer agents, anesthetic agent, drugs having an action on the central nervous system, protein, peptide, carbohydrate, polysaccharide, glycoprotein, lipid, hormone, growth factor, cytokine, interferon, receptor, antigen, allergen, antibody, substrate, metabolite, cofactor, inhibitor, drug, pharmaceutical, nutrient, toxin, poison, explosive, pesticide, chemical warfare agent, biowarfare agent, biohazardous agent, infectious agent, prion, radioisotope, vitamin, heterocyclic aromatic compound, carcinogen, mutagen, narcotic, amphetamine, barbiturate, hallucinogen, and vaccines against virus, bacterium, fungi, helminth, cancer,  Salmonella, Streptococcus, Brucella, Legionella, E. coli, Giardia, Cryptosporidium, Rickettsia , spore, mold, yeast, algae, amoebae, dinoflagellate, unicellular organism, pathogen, or combinations and mixtures thereof. 
     
     
         80 . The liquid formulation of  claim 35 , wherein the one or more active agents comprises an analgesic. 
     
     
         81 . The liquid formulation of  claim 35 , wherein the one or more active agents comprises an antitussive. 
     
     
         82 . The liquid formulation of  claim 35 , wherein the one or more active agents comprises a narcotic. 
     
     
         83 . The liquid formulation of  claim 35 , wherein the one or more active agents are disposed on a poly-lactic acid (PLA), poly-glycolic acid (PGA) and/or poly-lactic polyglycolic acid (PGLA) bead. 
     
     
         84 . A liquid, controlled-release formulation comprising controlled release microbeads comprising one or more active agents in coated drug-resin complexes, a dense, thixotropic solution having a density that is at or about the density of the one or more microbeads, said dense, thixotropic solution comprises a thixotropic agent, water and one or more preservatives, wherein said formulation is shelf-stable and has a uniform appearance with no visible lumps. 
     
     
         85 . The liquid, controlled-release of  claim 84 , wherein the microbeads are free of bubbles that cling to said microbeads and change their nominal density.